The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Acecainide     4-acetamido-N-(2- diethylaminoethyl)benzamide

Synonyms: Acekainid, Acecainida, Acecainidum, Lopac-A-5909, CHEMBL1097, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Acecainide


Psychiatry related information on Acecainide


High impact information on Acecainide


Chemical compound and disease context of Acecainide


Biological context of Acecainide


Anatomical context of Acecainide


Associations of Acecainide with other chemical compounds


Gene context of Acecainide


Analytical, diagnostic and therapeutic context of Acecainide


  1. Acecainide for ventricular arrhythmias. Vyden, J.K. JAMA (1982) [Pubmed]
  2. N-acetylprocainamide, torsades de pointes, and hemodialysis. Nguyen, K.P., Thomsen, G., Liem, B., Swerdlow, C.D., Franz, M.R. Ann. Intern. Med. (1986) [Pubmed]
  3. N-acetylprocainamide toxicity. Mitnick, P.D. Ann. Intern. Med. (1987) [Pubmed]
  4. N-acetylprocainamide is a less potent inducer of T cell autoreactivity than procainamide. Richardson, B., Cornacchia, E., Golbus, J., Maybaum, J., Strahler, J., Hanash, S. Arthritis Rheum. (1988) [Pubmed]
  5. Dose-ranging trial of N-acetylprocainamide in patients with premature ventricular contractions. Atkinson, A.J., Lee, W.K., Quinn, M.L., Kushner, W., Nevin, M.J., Strong, J.M. Clin. Pharmacol. Ther. (1977) [Pubmed]
  6. Hemodialysis for severe procainamide toxicity: clinical and pharmacokinetic observations. Atkinson, A.J., Krumlovsky, F.A., Huang, C.M., del Greco, F. Clin. Pharmacol. Ther. (1976) [Pubmed]
  7. Removal of toxic levels of N-acetylprocainamide with continuous arteriovenous hemofiltration or continuous arteriovenous hemodiafiltration. Domoto, D.T., Brown, W.W., Bruggensmith, P. Ann. Intern. Med. (1987) [Pubmed]
  8. cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. Urakami, Y., Akazawa, M., Saito, H., Okuda, M., Inui, K. J. Am. Soc. Nephrol. (2002) [Pubmed]
  9. Reduced acetylation of procainamide by para-aminobenzoic acid. Nylen, E.S., Cohen, A.I., Wish, M.H., Lima, J.J., Finkelstein, J.D. J. Am. Coll. Cardiol. (1986) [Pubmed]
  10. Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism. Okumura, K., Kita, T., Chikazawa, S., Komada, F., Iwakawa, S., Tanigawara, Y. Clin. Pharmacol. Ther. (1997) [Pubmed]
  11. Pharmacokinetics of N-acetylprocainamide in patients profiled with a stable isotope method. Atkinson, A.J., Ruo, T.I., Piergies, A.A., Breiter, H.C., Connelly, T.J., Sedek, G.S., Juan, D., Hubler, G.L., Hsieh, A.M. Clin. Pharmacol. Ther. (1989) [Pubmed]
  12. Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias. Harron, D.W., Brogden, R.N. Drugs (1990) [Pubmed]
  13. Acetylation of procainamide in man and its relationship to isonicotinic acid hydrazide acetylation phenotype. Gibson, T.P., Matusik, J., Matusik, E., Nelson, H.A., Wilkinson, J., Briggs, W.A. Clin. Pharmacol. Ther. (1975) [Pubmed]
  14. Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method. Strong, J.M., Dutcher, J.S., Lee, W.K., Atkinson, A.J. Clin. Pharmacol. Ther. (1975) [Pubmed]
  15. N-acetylprocainamide induced changes in refractoriness and monophasic action potentials of the dog heart in situ. Amlie, J.P., Landmark, K. Cardiovasc. Res. (1981) [Pubmed]
  16. N-acetylprocainamide and ischemia-induced ventricular fibrillation in the dog. Reynolds, R.D., Kamath, B.L. Eur. J. Pharmacol. (1979) [Pubmed]
  17. Clinical pharmacology and antiarrhythmic efficacy of N-acetylprocainamide. Winkle, R.A., Jaillon, P., Kates, R.E., Peters, F. Am. J. Cardiol. (1981) [Pubmed]
  18. Intravenous N-acetylprocainamide disposition kinetics in coronary artery disease. Kates, R.E., Jaillon, P., Rubenson, D.S., Winkle, R.A. Clin. Pharmacol. Ther. (1980) [Pubmed]
  19. Artificial kidneys and clearance calculations. Gibson, T.P., Matusik, E., Nelson, L.D., Briggs, W.A. Clin. Pharmacol. Ther. (1976) [Pubmed]
  20. Correlation of the electrophysiological and antiarrhythmic properties of the N-acetyl metabolite of procainamide with plasma and tissue drug concentrations in the dog. Bagwell, E.E., Walle, T., Drayer, D.E., Reidenbert, M.M., Pruett, J.K. J. Pharmacol. Exp. Ther. (1976) [Pubmed]
  21. Role of K+ channels in N-acetylprocainamide-induced relaxation of bovine tracheal smooth muscle. Nakahara, T., Moriuchi, H., Tanaka, Y., Yunoki, M., Kubota, Y., Sakamato, K., Shigenobu, K., Ishii, K. Eur. J. Pharmacol. (2001) [Pubmed]
  22. Effects of N-acetylprocainamide and sotalol on ion currents in isolated guinea-pig ventricular myocytes. Komeichi, K., Tohse, N., Nakaya, H., Shimizu, M., Zhu, M.Y., Kanno, M. Eur. J. Pharmacol. (1990) [Pubmed]
  23. Stability of standard curves prepared for EMIT homogeneous enzyme immunoassay kits stored at room temperature after reconstitution. Bach, P.R., Larsen, J.W. Clin. Chem. (1980) [Pubmed]
  24. Effects of antiarrhythmic drugs on phospholipid metabolism in Jurkat T cells. The potassium channel blocker, clofilium, specifically increases phosphatidylserine synthesis. Aussel, C., Pelassy, C. FEBS Lett. (1992) [Pubmed]
  25. Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. Somogyi, A., Bochner, F. British journal of clinical pharmacology. (1984) [Pubmed]
  26. Pharmacology of the class III antiarrhythmic agent sematilide in patients with arrhythmias. Wong, W., Pavlou, H.N., Birgersdotter, U.M., Hilleman, D.E., Mohiuddin, S.M., Roden, D.M. Am. J. Cardiol. (1992) [Pubmed]
  27. Pharmacokinetic and pharmacodynamic comparisons of twice daily and four times daily formulations of procainamide in patients with frequent ventricular premature depolarization. Yang, B.B., Abel, R.B., Uprichard, A.C., Smithers, J.A., Forgue, S.T. Journal of clinical pharmacology. (1996) [Pubmed]
  28. Cellular distribution of N-acetyltransferase activity in the rat small intestine. Ware, J.A., Reilly, T.P., Svensson, C.K. Biochem. Pharmacol. (1998) [Pubmed]
  29. Metoprolol or propranolol does not alter the kinetics of procainamide. Ochs, H.R., Carstens, G., Roberts, G.M., Greenblatt, D.J. J. Cardiovasc. Pharmacol. (1983) [Pubmed]
  30. Hemodynamic effects of N-acetylprocainamide in man: comparison with other antiarrhythmic drugs. Josephson, M.A., Singh, B.N. Angiology. (1986) [Pubmed]
  31. N-Acetylprocainamide kinetics after single and repeated oral doses. Ludden, T.M., Crawford, M.H. Clin. Pharmacol. Ther. (1982) [Pubmed]
  32. Fluoroimmunoassays for procainamide and N-acetylprocainamide compared with a liquid-chromatographic method. MacKichan, J.J., Coyle, J.D., Shields, B.J., Boudoulas, H., Lima, J.J. Clin. Chem. (1984) [Pubmed]
  33. Hemoperfusion for N-acetylprocainamide intoxication. Borkan, S.C. Ann. Intern. Med. (1986) [Pubmed]
  34. Determination of plasma procainamide and N-acetylprocainamide concentration by high-pressure liquid chromatography. Dutcher, J.S., Strong, J.M. Clin. Chem. (1977) [Pubmed]
WikiGenes - Universities